Drug Trial Radar · NCT06890611
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Oct 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
125
Actual
Start
Mar 25, 2025
Primary completion
Sep 26, 2025
Study completion Sep 26, 2025
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Mar 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.
Conditions
- Healthy
Interventions
BimagrumabDrug
Administered SC
TirzepatideDrug
Administered SC
Bimagrumab + Tirzepatide CoformulationDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of Bimagrumab Test MaterialTime frame: Predose through Week 13
- PK: Cmax of Bimagrumab Reference MaterialTime frame: Predose through Week 13
- PK: Cmax of Bimagrumab Coadministered with TirzepatideTime frame: Predose through Week 13
- PK: Cmax of Tirzepatide Coadministered with BimagrumabTime frame: Predose through Week 16
- PK: Cmax of Bimagrumab Coformulated with TirzepatideTime frame: Predose through Week 16
- PK: Cmax of Tirzepatide Coformulated with BimagrumabTime frame: Predose through Week 16
- PK: Area Under the Curve from Zero to Infinity AUC (AUC(0-∞)) of Bimagrumab Test MaterialTime frame: Predose through Week 13
- PK: AUC(0-∞) of Bimagrumab Reference MaterialTime frame: Predose through Week 13
- PK: AUC(0-∞) of Bimagrumab Coadministered with TirzepatideTime frame: Predose through Week 13
- PK: AUC(0-∞) of Tirzepatide Coadministered with BimagrumabTime frame: Predose through Week 16
- PK: AUC(0-∞) of Bimagrumab Coformulated with TirzepatideTime frame: Predose through Week 16
- PK: AUC(0-∞) of Tirzepatide Coformulated with BimagrumabTime frame: Predose through Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fortrea Clinical Research Unit
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.